[HTML][HTML] Secukinumab efficacy and safety in indian patients with moderate-to-severe plaque psoriasis: sub-analysis from FIXTURE, a randomized, placebo-controlled …
RM Bhat, B Leelavathy, SS Aradhya… - Indian dermatology …, 2017 - journals.lww.com
Background: Evidence has suggested Interleukin (IL)-17A to be an important effector
cytokine in the pathogenesis of psoriasis. Here, we report results for an Indian sub …
cytokine in the pathogenesis of psoriasis. Here, we report results for an Indian sub …
Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis
A Pinter, S Gerdes, C Papavassilis… - Journal of …, 2020 - Taylor & Francis
Background: Secukinumab is a fully human monoclonal antibody that neutralizes interleukin-
17A (IL-17A), a key cytokine involved in the development of psoriasis. Here, we …
17A (IL-17A), a key cytokine involved in the development of psoriasis. Here, we …
[HTML][HTML] Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study
A Blauvelt, DM Pariser, S Tyring, J Bagel… - Journal of …, 2023 - Elsevier
Abstract Background The IL-17A inhibitor secukinumab has demonstrated consistent
efficacy and safety in patients with moderate-to-severe plaque psoriasis, with normalization …
efficacy and safety in patients with moderate-to-severe plaque psoriasis, with normalization …
A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24 …
N Magnolo, K Kingo, V Laquer, J Browning… - Journal of the American …, 2022 - Elsevier
Background Psoriasis affects 0.13%-2.1% of children and adolescents. Despite a high
unmet need, the current treatment options approved for pediatric psoriasis are limited …
unmet need, the current treatment options approved for pediatric psoriasis are limited …
Secukinumab for treating plaque psoriasis
B Rothstein, A Gottlieb - Expert Opinion on Biological Therapy, 2016 - Taylor & Francis
Introduction: Plaque psoriasis is a chronic inflammatory disease that can result in significant
physical, psychological and quality of life impairments. Until recently, biologic treatment for …
physical, psychological and quality of life impairments. Until recently, biologic treatment for …
[HTML][HTML] Burden of moderate-to-severe plaque psoriasis and new therapeutic approaches (secukinumab): an Italian Perspective
L Mantovani, M Medaglia, P Piacentini, M Tricca… - Dermatology and …, 2016 - Springer
Psoriasis is a chronic immune-mediated inflammatory skin disease commonly categorized
as mild, moderate, or severe. Moderate-to-severe psoriasis is associated with significant …
as mild, moderate, or severe. Moderate-to-severe psoriasis is associated with significant …